Biotech Values

[willyw]

Yes, I saw. We are also seeing how quickly things are getting approved AND approvals from payors/insurance companies/agencies.

I rather expect Japan to also follow suit.
I've seen comments on this board remarking that China is streamlining approvals.

I also wonder if it will be true that relatively new therapies may also fade from usage?
Incivek, Victrelis, simeprevir had relatively short shelf lives.

What lies in store for Daclatasvir? Zepatier?

What are the implications for HCV drug therapies in trials? (JNJ, MRK)